Investor's Business Daily on MSN

Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117%

Biotech leader Stoke Therapeutics STOK offers a new buy point following a big rebound in recent weeks. That makes Stoke stock ...

Encoded Therapeutics Strengthens Clinical Leadership Team with Appointment of Professor Joseph Sullivan, M.D., as Vice President of Clinical Development

Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced the appointment of Dr. Joseph Sullivan M.D ...
Healio

Mortality risk elevated in patients with Lennox Gastaut, Dravet syndromes

Mortality rates for Lennox Gastaut syndrome and Dravet syndrome, both developmental epileptic encephalopathies, were ...
Science Daily

Scientists reveal the real benefits and hidden risks of medical cannabis

A sweeping review of more than 2,500 studies reveals that despite booming public enthusiasm, cannabis has strong scientific ...

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ...

Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...